Nostrum Laboratories Recalls Metformin Tablets Due to Elevated NDMA Levels

Nostrum Laboratories, Inc. recalled one lot of Metformin HCl Extended Release Tablets, USP 750 mg to the consumer level due to elevated levels of NNitrosodimethylamine (NDMA) levels above the Acceptable Daily Intake Limit.

Nostrum Laboratories, Inc. recalled one lot of Metformin HCl Extended Release Tablets, USP 750 mg to the consumer level due to elevated levels of NNitrosodimethylamine (NDMA) levels above the Acceptable Daily Intake Limit.

According to the Food and Drug Administration (FDA), NDMA is classified as a potential human carcinogen, a substance that could cause cancer.

Metformin Hydrochloride Extended-Release Tablets are used as a supplement to diet and exercise to improve blood sugar level in adults and pediatric patients with type 2 diabetes mellitus.

Nostrum Laboratories encourages patients that are taking the recalled medications to continue taking them and to contact their local pharmacist, physician or medical provider for advice regarding an alternative treatment.

There have been no reports of adverse reactions due to the recalled products thus far.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.